1. Home
  2. HCM

as of 03-16-2026 3:56pm EST

$14.32
+$0.04
+0.28%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Founded: 2000 Country:
Hong Kong
Hong Kong
Employees: 1811 City: N/A
Market Cap: 2.4B IPO Year: N/A
Target Price: $13.75 AVG Volume (30 days): 20.0K
Analyst Decision: Sell Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $11.51 - $19.50 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 28.37% Revenue Growth (next year): 17.50%
P/E Ratio: 5.49 Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered HCM Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 20 hours ago

AI Recommendation

hold
Model Accuracy: 75.78%
75.78%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest HUTCHMED (China) Limited News

HCM Breaking Stock News: Dive into HCM Ticker-Specific Updates for Smart Investing

All HCM News

Share on Social Networks: